Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780814 | 0.85 | IDO1 (0.53) | IDO1P2RX7MAPTMEN1HTT | |
| SCHEMBL25487719 | 0.81 | MTNR1A (0.44) | MAPTMEN1HTTKMT2APPARG | |
| SCHEMBL30302148 | 0.79 | RXRA (0.55) | IDO1P2RX7KDRPPARGPPARA | |
| SCHEMBL11434970 | 0.79 | IDO1 (0.54) | IDO1P2RX7MAPTMEN1HTT | |
| SCHEMBL1590516 | 0.79 | RXRA (0.55) | IDO1P2RX7KDRPPARGPPARA | |
| SCHEMBL1725225 | 0.78 | MAPT (0.37) | MAPTMEN1KMT2ALMNAMTNR1A | |
| SCHEMBL26091012 | 0.78 | CA2 (0.46) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL30349503 | 0.78 | CA2 (0.46) | MAPTMEN1HTTKMT2AKDM4E | |
| SCHEMBL31481163 | 0.77 | IDO1 (0.57) | IDO1P2RX7KDRPYCR1NPFFR2 | |
| SCHEMBL5264425 | 0.77 | IDO1 (0.57) | IDO1P2RX7KDRPYCR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-A | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| EP-4198024-A1 | PYRAZOLE MAGL INHIBITORS | H. Lundbeck A/S (DK) | 2023-06-21 | — | — | EP | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| CN-110678456-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2021-02-25 | — | — | US | disclosed |
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3630744-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110678456-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10266497-B2 | Pyrazole MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018217805-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180339970-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | IDO1 3336/4885P2RX7 296/4885MAPT 2499/4885 |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | IDO1 3336/4885P2RX7 296/4885MAPT 2499/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | IDO1 3331/4885P2RX7 316/4885MAPT 2487/4885 |
| US-10266497-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | IDO1 3336/4885P2RX7 296/4885MAPT 2499/4885 |
| US-20210053960-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | IDO1 3336/4885P2RX7 296/4885MAPT 2499/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | IDO1 3331/4885P2RX7 316/4885MAPT 2487/4885 |
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | IDO1 3336/4885P2RX7 296/4885MAPT 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.